Segment and Other Information - Summary of Net Sales by Medicine for Reportable Segments (Detail) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Segment Reporting Information [Line Items]
Total net sales	$ 885,245	$ 342,406
TEPEZZA [Member]
Segment Reporting Information [Line Items]
Total net sales	501,451	2,065
KRYSTEXXA [Member]
Segment Reporting Information [Line Items]
Total net sales	140,704	106,757
RAVICTI [Member]
Segment Reporting Information [Line Items]
Total net sales	78,257	72,817
PROCYSBI [Member]
Segment Reporting Information [Line Items]
Total net sales	49,571	43,363
ACTIMMUNE [Member]
Segment Reporting Information [Line Items]
Total net sales	31,435	28,763
UPLIZNA [Member]
Segment Reporting Information [Line Items]
Total net sales	30,477	1,873
BUPHENYL [Member]
Segment Reporting Information [Line Items]
Total net sales	2,161	1,660
QUINSAIR [Member]
Segment Reporting Information [Line Items]
Total net sales	296	209
Orphan Segment Net Sales [Member]
Segment Reporting Information [Line Items]
Total net sales	834,352	257,507
PENNSAID 2% [Member]
Segment Reporting Information [Line Items]
Total net sales	35,368	45,817
RAYOS [Member]
Segment Reporting Information [Line Items]
Total net sales	13,487	15,272
DUEXIS [Member]
Segment Reporting Information [Line Items]
Total net sales	1,123	19,465
VIMOVO [Member]
Segment Reporting Information [Line Items]
Total net sales	915	4,345
Inflammation [Member]
Segment Reporting Information [Line Items]
Total net sales	$ 50,893	$ 84,899